BioSpace News Archive

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in a fireside chat at the 2021 Wedbush PacGrow Healthcare Conference on Wednesday, August 11th at 2:55pm Eastern Time.

BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), today announced that the Japanese Patent Office (“JPO”) issued Japanese Patent No. 2019-189551 Notice of Allowance for the Company’s xB3-IDS fusion proteins.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will report its financial results for the second quarter ended June 30, 2021, and host a corporate update conference.

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

atai Life Sciences N.V., a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that it plans to host a conference call on Monday, August 16, 2021 at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2021 and provide a business update.

Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the appointment of Ameet Mallik to the Board of Directors.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the second quarter ended June 30, 2021 and provided corporate updates.

Reata Pharmaceuticals, Inc. today announced financial results for the quarter ended June 30, 2021, and provided an update on the Company’s business operations and clinical development programs.

Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2021.

IGM Biosciences, Inc. today announced its financial results for the second quarter ended June 30, 2021 and provided an update on recent developments.